NDLI: Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease

Content Provider	PubMed Central
Author	Jayanthi, Repalli Meruelo, Daniel
Copyright Year	2015
Abstract	Alzheimer’s disease, the most common type of dementia, is a progressive brain disease that destroys cognitive function and eventually leads to death. In patients with Alzheimer’s disease, beta amyloids and tau proteins form plaques/oligomers and oligomers/tangles that affect the ability of neurons to function properly. Heat shock protein 70 (HSP70) has the ability to prevent aggregation/oligomerization of beta amyloid/tau proteins, making it a potential drug target. To determine this potential, it is essential that we have appropriate in vitro and cell-based assays that help identify specific molecules that affect this aggregation or oligomerization through HSP70. Potential drug candidates could be identified through a series of assays, starting with ATPase assays, followed by aggregation assays with enzymes/proteins and cell-based systems. ATPase assays are effective in identification of ATPase modulators but do not determine the effect of the molecule on beta amyloid and tau proteins. Molecules identified through ATPase assays are validated by thioflavin T aggregation assays in the presence of HSP70. These assays help uncover if a molecule affects beta amyloid and tau through HSP70, but are limited by their in vitro nature. Potential drug candidates are further validated through cell-based assays using mammalian, yeast, or bacterial cultures. However, while these assays are able to determine the effect of a specific molecule on beta amyloid and tau, they fail to determine whether the action is HSP70-dependent. The creation of a novel, direct assay that can demonstrate the antiaggregation effect of a molecule as well as its action through HSP70 would reduce the number of false-positive drug candidates and be more cost-effective and time-effective.
Related Links	http://dx.doi.org/10.2147/dddt.s72165
Ending Page	331
Starting Page	321
File Format	PDF
ISSN	11778881
e-ISSN	11778881
Journal	Drug Design, Development and Therapy
Volume Number	9
Language	English
Publisher	Dove Medical Press
Publisher Date	2015-01-01
Access Restriction	Open
Rights Holder	Dove Medical Press
Subject Keyword	Pharmacology Drug Discovery Pharmaceutical Science Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Drug Discovery Pharmacology Pharmaceutical Science

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease

Disease-modifying drugs in Alzheimer’s disease

Advances with RNA interference in Alzheimer’s disease research

New Approaches to Treating Alzheimer’s Disease

Targeting the hypoxia pathway to treat pancreatic cancer

Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease

Similar Documents

Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease

Disease-modifying drugs in Alzheimer’s disease

Advances with RNA interference in Alzheimer’s disease research

New Approaches to Treating Alzheimer’s Disease

Targeting the hypoxia pathway to treat pancreatic cancer

Development of a robust cell-based high-throughput screening assay to identify targets of HIV-1 viral protein R dimerization

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease

Neuroprotective effects of salidroside through PI3K/Akt pathway activation in Alzheimer’s disease models

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]

Screening strategies to identify HSP70 modulators to treat Alzheimer’s disease